Etodolac

Non-steroidal anti-inflammatory drug (NSAID), Pyranocarboxylic acid derivative

Etodolac

Lodine (US brand discontinued); generic

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary

Classes

Non-steroidal anti-inflammatory drug (NSAID), Pyranocarboxylic acid derivative

Common uses

Osteoarthritis▲0▼, Rheumatoid arthritis▲0▼, Acute musculoskeletal pain▲0▼

Pharmacy

Starting dose

IR 200-400 mg PO every 6-8 hours; ER 400-1000 mg PO once daily

Preparations

200, 300, 400, 500 mg IR tablets/capsules; 400, 500, 600 mg ER tablets

US FDA Max

1000 mg/d (osteoarthritis); 1200 mg/d (rheumatoid arthritis)

Pharmacology

Routes

Oral

Onset

Analgesia within 30 minutes; full anti-inflammatory effect over days

Duration

6-8 hours (IR); 24 hours (ER)

Half-life

~7 hours

Bioavailability

~100% (oral; absorption complete)

Pregnancy

Avoid after 20 weeks (NSAID-class FDA 2020 advisory).^{[citation needed]}

Legal status

Rx-only in US. NSAID-class Boxed Warning for CV thrombotic events and GI bleeding

Purported mechanism

Etodolac is a non-selective COX inhibitor with some preferential COX-2 binding at therapeutic concentrations, producing the typical anti-inflammatory, analgesic, and antipyretic effects of the NSAID class.▲0▼ Renal, GI, hypertensive, and CV effects parallel the class profile; modest COX-2 preference may underlie some literature suggesting slightly better GI tolerability than non-selective NSAIDs, though clinically the difference is small.